ATE553130T1 - Humanisierter anti-human-osteopontin-antikörper - Google Patents

Humanisierter anti-human-osteopontin-antikörper

Info

Publication number
ATE553130T1
ATE553130T1 AT07815053T AT07815053T ATE553130T1 AT E553130 T1 ATE553130 T1 AT E553130T1 AT 07815053 T AT07815053 T AT 07815053T AT 07815053 T AT07815053 T AT 07815053T AT E553130 T1 ATE553130 T1 AT E553130T1
Authority
AT
Austria
Prior art keywords
human osteopontin
humanized anti
antibodies
osteopontin antibodies
human
Prior art date
Application number
AT07815053T
Other languages
English (en)
Inventor
Nobuchika Yamamoto
Fumihiko Sakai
Hirofumi Higuchi
Masaharu Torikai
Toshihiro Nakashima
Original Assignee
Astellas Pharma Inc
Chemo Sero Therapeut Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Chemo Sero Therapeut Res Inst filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE553130T1 publication Critical patent/ATE553130T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT07815053T 2006-05-31 2007-05-30 Humanisierter anti-human-osteopontin-antikörper ATE553130T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006152892 2006-05-31
PCT/JP2007/061026 WO2007139164A1 (ja) 2006-05-31 2007-05-30 ヒト化抗ヒトオステオポンチン抗体

Publications (1)

Publication Number Publication Date
ATE553130T1 true ATE553130T1 (de) 2012-04-15

Family

ID=38778682

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07815053T ATE553130T1 (de) 2006-05-31 2007-05-30 Humanisierter anti-human-osteopontin-antikörper

Country Status (17)

Country Link
US (1) US7807161B2 (de)
EP (1) EP2025749B8 (de)
JP (1) JP4064441B2 (de)
KR (1) KR20090024748A (de)
CN (1) CN101495632B (de)
AT (1) ATE553130T1 (de)
AU (1) AU2007268591A1 (de)
BR (1) BRPI0711229A2 (de)
CA (1) CA2653661A1 (de)
ES (1) ES2384350T3 (de)
IL (1) IL195503A0 (de)
MX (1) MX2008015309A (de)
NO (1) NO20085282L (de)
RU (1) RU2429016C2 (de)
TW (1) TW200813087A (de)
WO (1) WO2007139164A1 (de)
ZA (1) ZA200810863B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711882C (en) 2008-01-11 2016-07-19 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Improved humanized anti-human .alpha.9-integrin antibody
JP5339748B2 (ja) * 2008-03-11 2013-11-13 国立大学法人北海道大学 ヒトオステオポンチンの活性化を阻害する物質をスクリーニングする方法
US8614296B2 (en) * 2008-04-24 2013-12-24 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
CA2778401C (en) 2009-10-21 2019-08-13 Hiroshima University Integrin alpha 8-beta 1-specific monoclonal antibody
WO2012050646A2 (en) 2010-06-29 2012-04-19 The Trustees Of The University Of Pennsylvania Biomimetic chemical sensors using nanoelectronic readout of olfactory receptors
WO2013033359A1 (en) * 2011-08-31 2013-03-07 The Trustees Of The University Of Pennsylvania Carbon nanotube biosensors and related methods
WO2014061783A1 (ja) 2012-10-19 2014-04-24 株式会社イーベック クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
TW201623329A (zh) * 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
WO2016036950A1 (en) 2014-09-05 2016-03-10 The Trustees Of The University Of Pennsylvania Volatile organic compound-based diagnostic systems and methods
US11300162B2 (en) 2016-07-06 2022-04-12 Dana Automotive Systems Group, Llc Axle and propeller shaft quick-connect joint attachment assembly
KR20180000875U (ko) 2016-09-21 2018-03-29 전은희 조명 모듈
CN112480250B (zh) * 2020-12-23 2022-03-15 上海交通大学 一种抗人骨桥蛋白的抗体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69433422T2 (de) 1993-03-11 2004-09-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Monoklonaler anti-hiv antikörper
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
ATE253593T1 (de) * 1996-07-16 2003-11-15 Plueckthun Andreas Prof Dr Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
ATE412013T1 (de) 2001-04-05 2008-11-15 Immuno Biological Lab Co Ltd Anti-osteopontin-antikörper und dessen verwendung
CA2453662A1 (en) * 2001-07-19 2003-01-30 Stefan Ewert Modification of human variable domains
US7241873B2 (en) 2001-09-25 2007-07-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant anti-osteopontin antibody and use thereof
EP1551453A4 (de) * 2002-06-17 2007-04-25 Us Gov Health & Human Serv Spezifitätsgrafting eines mäuseantikörpers auf ein menschliches gerüst
WO2004103403A1 (ja) 2003-05-23 2004-12-02 Immuno-Biological Laboratories Co., Ltd. 免疫担当細胞活性化阻害剤およびその用途
EP1805220A1 (de) 2004-10-13 2007-07-11 Genentech, Inc. Verfahren zur behandlung von tumoren mitantiosteopontin-antikörpern
JP2006152892A (ja) 2004-11-29 2006-06-15 Anest Iwata Corp 気体吸排機械
EP1860120B1 (de) * 2005-02-08 2018-01-24 The Chemo-Sero-Therapeutic Research Institute Verfahren für einen verbesserten antikörper

Also Published As

Publication number Publication date
ES2384350T3 (es) 2012-07-04
ZA200810863B (en) 2010-08-25
IL195503A0 (en) 2011-08-01
JP4064441B2 (ja) 2008-03-19
US20090053212A1 (en) 2009-02-26
EP2025749A4 (de) 2009-12-16
CN101495632B (zh) 2011-08-03
EP2025749B1 (de) 2012-04-11
BRPI0711229A2 (pt) 2013-01-08
WO2007139164A1 (ja) 2007-12-06
RU2008152769A (ru) 2010-07-20
EP2025749A1 (de) 2009-02-18
KR20090024748A (ko) 2009-03-09
NO20085282L (no) 2009-02-26
MX2008015309A (es) 2009-03-02
TW200813087A (en) 2008-03-16
EP2025749B8 (de) 2012-05-23
CA2653661A1 (en) 2007-12-06
JP2008005836A (ja) 2008-01-17
RU2429016C2 (ru) 2011-09-20
CN101495632A (zh) 2009-07-29
AU2007268591A1 (en) 2007-12-06
US7807161B2 (en) 2010-10-05

Similar Documents

Publication Publication Date Title
ATE553130T1 (de) Humanisierter anti-human-osteopontin-antikörper
ATE535545T1 (de) Chimäre und humanisierte monoklonale antikörper gegen interleukin-13
WO2005092926A3 (en) Reducing the risk of human and anti-human antibodies through v gene manipulation
NO20190202A1 (no) Anvendelse av anti-CGRP antagonist antistoff
NL1027975A1 (nl) Antilichamen tegen MAdCAM.
RS53760B1 (en) HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
NL1032132A1 (nl) Nieuwe MAdCAM-antilichamen.
ATE512986T1 (de) Antikörper gegen clostridium difficile-toxine und ihre verwendung
LTPA2016026I1 (lt) Anti-il-17 antikūnai
NZ595464A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
EA200702008A1 (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
ATE520716T1 (de) Humanisierter anti-cd4-antikörper mit immunsuppressiven eigenschaften
RS53984B1 (en) IP-10 ANTIBODIES AND THEIR USES
WO2007129895A3 (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
BRPI0811526A2 (pt) uso de um anticorpo monoclonal, quimérico, humanizado ou humano que liga o il-5r, anticorpo anti-il-5r isolado, e, epítopo isolado de il-5r alfa
DE602005022928D1 (de) Antikörper gegen gpnmb und ihre verwendungen
RS53793B1 (en) HUMANIZED ANTIBODIES AGAINST BETA AMYLOID
DK2171060T3 (da) Superagonistisk anti-CD28-antistof
BRPI0821211A2 (pt) Anticorpo anti-humano cd34 humanizado, o método de preparação e usos do mesmo.
DK1519748T3 (da) Mikropartikler med CD28-specifikke monoklonale antistoffer
WO2004108766A3 (en) Anti-hgf-r antibodies and their use
MX2009005103A (es) Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo.
DK1907854T3 (da) Monoklonale antistoffer, hybridomcellelinjer, fremgangsmåder og kits til detektion af phytase
BRPI0509495A2 (pt) anticorpo humanizado
ATE484749T1 (de) Von anti-trichinella-antikörpern erkannte polypeptide und ihre verwendung